Stock Intellegince NTLA Intellia Therapudics

Market note · October 1, 2026

Intellia (NASDAQ: NTLA) at $12.12: Coil, Not a Breakout

A levels-and-scenarios playbook for the in-vivo CRISPR name. Tape read as of the October 1, 2026 close.

Disclaimer. This is market commentary, not investment advice, a solicitation, or a recommendation to buy or sell any security. Biotech is binary. A safety headline, a trial delay, or a financing can gap through any stop. Scenario probabilities are subjective weights based on price structure, volume, and public disclosures as of October 1, 2026. They are not forecasts. Intellia is pre-commercial, cash-burning, and heavily shorted. Do your own research or consult a licensed adviser. Past performance is not indicative of future results.

Intellia is coiling, not breaking out. At about $12.12 the stock is pinned on the 50-day moving average near $12 and still under the 200-day near $12.84. It is roughly 57 percent below the 52-week high of $28.25 and about 52 percent above the 52-week low of $7.95. Today’s gain was only about 0.5 percent, but volume was about 7.44 million versus a three-month average near 3.93 million, or roughly 1.9 times normal. That is accumulation interest, not confirmation.

After-hours was unchanged at $12.12. The session opened at $11.98 against a prior close of $12.06. Some feeds printed a wider day range, into the mid-$12s, so treat $12.12 as the reference print, not a guaranteed close on every vendor. Market cap is about $1.70 billion. Beta is about 1.82. Next earnings window is November 4–9, 2026, with November 5 before the open as the working estimate. There is no dividend. Trailing EPS is about −$3.36, so P/E is not usable. P/S is about 28.5 and P/B is about 2.33 on book value of $5.20.

Snapshot

Swipe the table sideways on a phone. Numbers stay on one line.

Item	Level	Read
Last / after hours	$12.12 / $12.12	Flat after a small up day
Open / prior close	$11.98 / $12.06	Held the prior close
Volume	7.44M vs 3.93M avg	About 1.9× average. Active, not decisive.
52-week range	$7.95 – $28.25	About 52% above the low, 57% below the high
Moving averages	50-day ~$12 / 200-day ~$12.84	On the 50-day, still under the 200-day
RSI (14)	about 52	Neutral. Not overbought.
Market cap	about $1.70B	Small-cap biotech
Beta	1.82	Gaps are normal
Cash (Jun 30)	$628 million	Company says runway into 2028
P/S · P/B	28.5 · 2.33	Sales multiple is pipeline, not revenue
Next earnings	Nov 4–9, 2026	Update catalyst, not the main event

What the stock is actually trading

Two programs dominate the equity. Lonvo-z, for hereditary angioedema, is the nearer commercial path. Phase 3 HAELO met its primary and key secondary endpoints, the data were published in the New England Journal of Medicine, and the FDA accepted the biologics license application on September 8, 2026 with priority review. The PDUFA target action date is March 10, 2027. The agency is not currently planning an advisory committee. Intellia has been building a launch team and is aiming for a U.S. launch in the first half of 2027 if approved. That would be a candidate for the first in-vivo CRISPR therapy approval.

Nex-z, for transthyretin amyloidosis, is the overhang. The FDA placed clinical holds on MAGNITUDE (ATTR cardiomyopathy) and MAGNITUDE-2 (ATTR polyneuropathy) on October 29, 2025 after a Grade 4 liver-enzyme and bilirubin event in a MAGNITUDE patient that met the trial’s pausing rules. A study participant died. The MAGNITUDE-2 hold was lifted in late January 2026. The MAGNITUDE hold was lifted on March 2, 2026. Restart conditions include tighter liver-lab monitoring, short-course steroids if enzymes rise after dosing, exclusion of certain liver abnormalities, and, for MAGNITUDE, exclusion of recent cardiovascular instability and ejection fraction below 25 percent. The company has also flagged an HLA-C*05:01 allele as a risk marker for liver-enzyme elevations and has added HLA typing. Enrollment has resumed. The safety scar is why the stock is $12 and not $28.

Cash, cash equivalents, and marketable securities were $628.4 million at June 30, 2026, after an April equity offering that raised about $195 million net. Management says that funds operations at least into 2028, excluding product revenue. Dilution risk is lower than it was, not gone.

Sentiment

The Street is split. The short book is not.

Signal	Reading	Implication
Analyst rating	Hold to Buy, depending on the panel. About 19–23 analysts. Sells are present.	Not a clean consensus
Average target	$21 – $24	About +73% to +98% from $12.12
Target range	about $5–$9 low / $49–$61 high	The spread is the risk
Recent calls	Citizens Outperform $30; H.C. Wainwright Buy $25; Chardan Buy near $27; Wedbush Neutral $13; Morgan Stanley Hold $15; Goldman Sell $9	Bulls own the upside. Bears own the floor.
Short interest	About 45–47 million shares, roughly 33–35% of float, 9–14 days to cover. Up versus the prior month on one panel.	Crowded short. Squeeze fuel and real skepticism.
Sponsorship	Institutions dominate the float. ARK has been adding shares in recent sessions.	A buyer of dips exists
Balance sheet	$628 million cash. Runway guided into 2028. April raise already done.	No forced financing this quarter
Overhangs	Nex-z liver toxicity and a patient death. Restart exclusions narrow the ATTR-CM population. Lonvo-z still needs approval. Collaboration revenue is falling.	Multiple stays capped until safety is boring

Is it ready to break out?

No. The structure is a base under the 200-day, not a breakout.

What is working: price is holding the 50-day near $12, volume is almost double average, RSI is neutral, the lonvo-z BLA is accepted with a March 10, 2027 PDUFA date, both nex-z holds are lifted, and the short book is large enough to fuel a squeeze if a clean update hits.

What is missing: a close above the 200-day and the $13.00–$13.50 supply zone. A 0.5 percent day does not reset a 57 percent drawdown from the high. The market is still discounting another liver event, a slower MAGNITUDE restart, or a lonvo-z review surprise. Earnings in early November can move the stock, but they are not the PDUFA.

Breakout confirmation is a daily close above $13.00 on volume at or above the 3.93 million average, then a hold of $12.80–$13.00 as support. Until that prints, treat $12.50–$13.00 as supply.

Levels from $12.12

Percentages are versus a $12.12 reference, not a recommendation to trade that price.

Level	Role	Move vs $12.12
$7.95	52-week low / tail	−34%
$9.50 – $10.00	Breakdown magnet	−22% to −17%
$11.20	Swing invalidation	−7.6%
$11.80 – $12.00	50-day / first support	−2.6% to −1.0%
$12.50	Near-term supply	+3.1%
$12.84	200-day moving average	+5.9%
$13.00 – $13.50	Breakout trigger	+7% to +11%
$15.00	First real target	+24%
$18.00	Squeeze / gap zone	+49%
$21 – $24	Consensus target band	+73% to +98%
$28.25	52-week high	+133%

Playbook

These are scenario weights, not forecasts. Size for a name that can move 8 to 15 percent on a headline. Probabilities are a map of paths. They are not a promise, and they do not need to sum to 100 because paths overlap.

Setup	Trigger	Stop	Target	Reward vs $12.12	Probability	Invalidation
A. Range coil	Fails under $12.80–$13.00	—	$11.80 then $11.20	−3% to −8%	about 40%	Close above $13
B. Swing long	Hold $11.80–$12.00, or buy the $13 reclaim	$11.20 (−8%)	$13.50 / $15.00	+11% / +24%	about 25%	Lose $11.20
C. Confirmed breakout	Daily close above $13 on at least average volume, and $12.80 holds	$12.40	$15.00 then $18.00	+24% / +49%	about 20%	Back under $12.40
D. Catalyst rerate	Clean nex-z enrollment update plus lonvo-z review stays on the March 10, 2027 path	Trail under $15	$21 then $24	+73% to +98%	about 15%	New liver event or a review delay
E. Breakdown	Close under $11.20	—	$10.00 then $7.95	−17% to −34%	about 20%	Reclaim $12.00

If you want the long

1. Aggressive. A starter only while $11.80–$12.00 holds. Stop $11.20. First scale at $12.80. Core exit $15. Risk is about 8 percent for an 11 to 24 percent target. Use a partial size. A liver headline does not respect the stop.
2. Cleaner. Wait for the $13.00 close. Enter $13.05–$13.30. Stop $12.40. Targets $15 (about +13 to +15 percent from entry) and $18 (about +35 to +38 percent from entry). Lower hit rate on the trigger, better structure, and the short cover can do more of the work.
3. Do not carry a full position into November 4–9, or into any nex-z safety update. Earnings are a volatility event. The real repricing, if it comes, is a clean restart plus an uneventful lonvo-z review into the March 10, 2027 PDUFA date. That is a months-long path, not a one-day breakout.

The base case into November is more chop between $11.20 and $13.00 than a trend. The asymmetric upside lives only after $13 is reclaimed and held, and only if nex-z stays quiet. Below $11.20 the coil is wrong, and the next magnet is $10, with $7.95 as the tail. The short interest makes both directions sharper than the chart looks.

Again, not advice. Levels, stops, targets, and probabilities are a framework for reading the tape, not instructions. Stops are not guaranteed in a fast biotech tape. Analyst targets are opinions and disagree by a wide margin. Short interest figures differ by vendor and settlement date; the latest panels cluster around one-third of the float. Cash and runway figures are from the August 6, 2026 update. The lonvo-z PDUFA date is a target, not an approval. Verify every number before you use it.